Additional Information

Description

Remicade PR 100 mg is a monoclonal antibody-based biological agent containing infliximab. It is classified as a tumor necrosis factor-alpha (TNF-a) inhibitor, designed to neutralize the activity of TNF-a, a pro-inflammatory cytokine implicated in autoimmune disorders. By blocking TNF-a, the drug reduces inflammation and modulates immune system activity, providing therapeutic effects in chronic inflammatory conditions.

This medication is indicated for the treatment of autoimmune diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is often used in patients who have had an inadequate response to conventional therapies, such as disease-modifying antirheumatic drugs (DMARDs) or corticosteroids.

Common adverse effects include infusion-related reactions, respiratory infections, headache, and fatigue. Serious adverse events may include an increased risk of severe infections, tuberculosis reactivation, malignancies, hepatotoxicity, and demyelinating diseases. Patients should undergo tuberculosis screening and other relevant tests before initiation.